Actively Recruiting
Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies
Led by NYU Langone Health · Updated on 2026-02-27
70
Participants Needed
1
Research Sites
234 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to test the efficacy and feasibility of an intervention protocol for home-based repetitive transorbital alternating current stimulation (rtACS) for the treatment of visual impairment in people with optic neuropathy. The primary aims are to evaluate the effectiveness of home-based rtACS to ameliorate the progressive effects of vision loss functionally in the eye and the visual pathway, and in regard to people's independence (i.e., functional ability).
CONDITIONS
Official Title
Repetitive Transorbital Alternating Current Stimulation for Optic Neuropathies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age equal to or over 18 years old
- Must have a permanent residence
- Diagnosis of optic neuropathy
- Visual field defects present in at least one eye (MD ≤ -3.00 dB) with false loss, false positive, false negative <33%
- Visual Field Index (VFI) between 10% and 90%
- Clear optical apparatus
- Best-corrected visual acuity of 20/400 or better in at least one eye
- Commitment to follow study procedures including 8-week intervention (30 sessions every other day), baseline, post-intervention, and two follow-up visits
- If unable to perform the intervention independently due to visual impairment or other conditions, assistance from a family member or caregiver is required
You will not qualify if you...
- High intraocular pressure over 27 mmHg
- End-stage organ disease or medical conditions causing vision loss (e.g., diabetes, stroke)
- Advanced or unstable retinal diseases
- Pathological nystagmus
- Acute conjunctivitis
- Photosensitivity to flickering lights
- Eye or non-eye surgery within 2 months prior to enrollment
- Presence of electric or electronic implants (e.g., cardiac pacemaker)
- Metallic implants in head or torso (titanium screws and dental implants allowed)
- Diagnosed epilepsy under medical treatment
- Acute stage autoimmune diseases (e.g., rheumatoid arthritis)
- Metastatic disease
- Certain mental or psychiatric disorders (e.g., schizophrenia) affecting ability to participate
- Chronic unstable medical conditions that may cause missed visits or interventions
- History of addiction without at least one year of abstinence
- Uncontrolled systemic hypertension (BP > 160/100 mmHg)
- Pregnant, breastfeeding, or planning pregnancy
- Severe skin conditions near stimulation sites
- Clinically unstable intraocular pressure
- Complete blindness in both eyes
- Non-resected brain tumors
- Unstable diabetic retinopathy in the study eye
- Optic neuropathies due to brain tumors
- Inability to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NYU Langone Health
New York, New York, United States, 10022
Actively Recruiting
Research Team
A
Angeles Ramos, MD
CONTACT
M
Maria de los Angeles Ramos, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here